Samarium Therapy
Samarium Therapy is a radiopharmaceutical treatment modality that employs samarium-153 lexidronam, a beta-emitting radionuclide, to selectively target and ablate metastatic bone lesions for the palliation of cancer-induced skeletal pain.
27
Publications
1.2K
Citations
175
Authors
65
Institutions
Publications per year
2017–2026
0
Variants
Samarium-153 Lexidronam Therapy
Parents
27
Jiahe Tian, Jinming Zhang, Qing-tian Hou et al. · European Journal of Nuclear Medicine and Molecular Imaging · 1999 · 110 citations
Medicine, Nuclear Medicine, Oncology +16
1–5 of 27
175
NewYork–Presbyterian Brooklyn Methodist Hospital, United States
2 publications · 76 citations
2
h-index
NewYork–Presbyterian Brooklyn Methodist Hospital, United States
2 publications · 76 citations
2
h-index
2
h-index
2
h-index
Memorial Sloan Kettering Cancer Center, United States
2 publications · 126 citations
2
h-index
1–5 of 175
65

Cornell University
Ithaca, United States
4 h-index
37 publications
2.5K citations

NewYork–Presbyterian Brooklyn Methodist Hospital
Brooklyn, United States
2 h-index
11 publications
397 citations
Memorial Sloan Kettering Cancer Center
New York, United States
2 h-index
30 publications
2.2K citations
University Hospital Münster
Münster, Germany
2 h-index
3 publications
133 citations
The University of Texas MD Anderson Cancer Center
Houston, United States
1 h-index
1 publications
81 citations
Cancer Clinic
Bryan, United States
1 h-index
8 publications
176 citations
Misericordia Community Hospital
Edmonton, Canada
1 h-index
1 publications
10 citations
Deenanath Mangeshkar Hospital and Research Center
Pune, India
1 h-index
1 publications
11 citations
1–8 of 65
Repository · 3 publications · 67 citations
3
h-index
2 publications · 273 citations
2
h-index
2 publications · 84 citations
2
h-index
2 publications · 126 citations
2
h-index
2 publications · 210 citations
2
h-index
1–5